FT News Briefing Lilly Covid drug, Vatican derivatives, UK mining corruption probe
Oct 8, 2020
In this engaging discussion, Tom Burgess, an FT investigations correspondent known for his incisive reporting, dives into the controversy surrounding Eli Lilly's urgent request for Covid-19 antibody approval. He also unpacks the Vatican's dubious investment in derivatives, questioning the morality behind using charity funds. Most chillingly, he investigates the mysterious deaths of two potential witnesses linked to a high-stakes mining corruption case, shedding light on the dark underbelly of corporate misconduct and the risks faced by whistleblowers.
AI Snips
Chapters
Transcript
Episode notes
Lilly's COVID-19 Treatment
- Eli Lilly's COVID-19 antibody treatment seeks emergency authorization.
- This could be among the first treatments for mild to moderate cases.
Vatican's Hertz Investment
- The Vatican invested charitable donations in Hertz credit default swaps.
- This was done under Cardinal Becciu, who was later stripped of his rights.
Mysterious Deaths in Missouri
- Two potential witnesses in a UK mining corruption probe died in Missouri.
- Their deaths were initially attributed to malaria.